UBS AM
RAPT

UBS AM’s RAPT Therapeutics RAPT Stock Holding History

UBS AM’s Portfolio RAPT Stock Details RAPT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q2 		– Sell
-34,387
Closed -$2.47M – 2865
2024
Q1 		$2.47M Sell
34,387
-96
-0.3% -$13.3K ﹤0.01% 1578
2023
Q4 		$6.86M Sell
34,483
-111
-0.3% -$13.7K ﹤0.01% 1126
2023
Q3 		$4.6M Buy
+34,594
New +$5.65M ﹤0.01% 1240
2022
Q4 		– Sell
-1,498
Closed -$288K – 2708
2022
Q3 		$288K Hold
1,498
– – ﹤0.01% 2502
2022
Q2 		$219K Buy
+1,498
New +$200K ﹤0.01% 2563
2022
Q1 		– Sell
-1,831
Closed -$538K – 2813
2021
Q4 		$538K Hold
1,831
– – ﹤0.01% 2523
2021
Q3 		$455K Buy
1,831
+943
+106% +$249K ﹤0.01% 2534
2021
Q2 		$226K Buy
+888
New +$166K ﹤0.01% 2696

Other funds holding RAPT

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
CG
Column Group San Francisco, California $101M AUM 290.34% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
KCM
Kingdon Capital Management New York $911M AUM 51.11% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
Deutsche Bank
Deutsche Bank Frankfurt Am Main Ge, Germany $303B AUM 30.15% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return
Federated Hermes
Federated Hermes Pittsburgh, Pennsylvania $61.5B AUM 30.7% 1-Year Est. Return

UBS AM's RAPT Position: Q2 2024 in Review

UBS AM sold out of RAPT Therapeutics (RAPT) in Q2 2024, closing a stake of 34,387 shares — an estimated $2.47M sold.

UBS AM first reported a position in RAPT in Q2 2021 and held it in 8 quarters. The position peaked at $6.86M in Q4 2023. 103 funds tracked by Wall St. Rank hold RAPT as of Q2 2024.

  • UBS AM reported no remaining RAPT Therapeutics position as of Q2 2024 after selling out during the quarter.
  • UBS AM sold 34,387 RAPT Therapeutics shares in Q2 2024, an estimated $2.47M.
  • UBS AM first reported a position in RAPT Therapeutics in Q2 2021 and held it in 8 quarters.
  • UBS AM's RAPT Therapeutics position peaked at $6.86M in Q4 2023.
  • 103 funds tracked by Wall St. Rank held RAPT Therapeutics as of Q2 2024.

Based on UBS AM's 13F filing for Q2 2024, filed 14 Aug 2024.